Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure
| Autor: | Jan L. Posma, Suzan Willemsen, Dirk J. van Veldhuisen, Leen M. van Wijk, Yoran M. Hummel, Jasper W. L. Hartog, Adriaan A. Voors |
|---|---|
| Přispěvatelé: | Cardiovascular Centre (CVC) |
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Glycation End Products
Advanced Male Ventricular Function Left EXERCISE CAPACITY law.invention VENTRICULAR EJECTION FRACTION chemistry.chemical_compound Randomized controlled trial law Diastole Surveys and Questionnaires Health Status Indicators Ejection fraction Exercise Tolerance Dilated cardiomyopathy STIFFNESS Middle Aged RANDOMIZED CONTROLLED-TRIAL DIASTOLIC FUNCTION PROGNOSTIC VALUE Research Design Cardiology Advanced glycation end-product Female Cardiology and Cardiovascular Medicine medicine.drug Echocardiography Stress medicine.medical_specialty Systole Heart failure Placebo Alagebrium Oxygen Consumption Double-Blind Method Internal medicine medicine Humans Advanced glycation end-products HYPERTENSION business.industry AGE breaker Stroke Volume SKIN AUTOFLUORESCENCE medicine.disease DILATED CARDIOMYOPATHY DYSFUNCTION Thiazoles chemistry Exercise Test business |
| Zdroj: | European Journal of Heart Failure, 12(3), 294-300. Wiley |
| ISSN: | 1879-0844 1388-9842 |
| Popis: | Aims Previous small open label studies have shown that the advanced glycation end-product (AGE) breaker alagebrium may improve cardiac function in patients with chronic heart failure (HF). We report the design, methods and baseline characteristics of a double-blind, placebo-controlled, randomized trial evaluating the efficacy and safety of alagebrium (BENEFICIAL) in patients with HF and a left ventricular ejection fraction (LVEF) ≤ 0.45. Methods and results Patients with NYHA II–IV stable HF for at least 3 months were eligible for this study. One hundred and two patients were included in the study and randomized to either 200 mg alagebrium twice daily or placebo for a period of 36 weeks. The mean age of patients was 60 ± 11 years, 78% were male, and 17% were diabetic. Mean peak VO2 was 21.7 ± 5.9 mL/min/kg, mean LVEF was 0.32 ± 0.09. Diastolic function was worse (mean early tissue diastolic velocity (E′) 4.6 ± 1.7 vs. 6.1 ± 2.0 cm/s; P < 0.001) in patients with LVEF ≤ 0.35 compared to patients with LVEF between 0.35 and 0.45. Conclusion The BENEFICIAL study is a proof-of-concept study that will provide new data on the efficacy and safety of the AGE crosslink breaker alagebrium in systolic HF patients. EudraCT number of this trial is NCT00516646. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|